The era when a clinical failure in Alzheimer's disease (AD) meant major headlines, stock sell-offs and conference calls attempting damage control seems to be over, as two pharma giants – this year and last year – practically murmured their mid and late-stage blowups with AD candidates in the 5HT6 receptor antagonist class.